FibroGen (FGEN) Reports Q1 Loss of $0.53/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
FibroGen Reports First Quarter 2019 Financial Results
May 9, 2019 4:45 PM EDTPositive topline results from pooled safety analyses of roxadustat Phase 3 global programCompleted one year of treatment in Phase 2 trial evaluating pamrevlumab in treatment of non-ambulatory DMD patients
Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time
SAN FRANCISCO, May 09, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter of 2019 and provided an update on the companys recent developments.
The first quarter of 2019 saw critical execution across multiple programs.... More
